Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
Kawamura
Satoshi
S
Sakai
Akio
A
Endo
Tomomichi
T
Maruta
Masaki
M
D000293:Adolescent; D000077465:Cabergoline; D019955:Conduct Disorder / Q000209:etiology* / Q000523:psychology*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007333:Insulin Resistance; D008572:Menarche / Q000523:psychology; D000077205:Pioglitazone; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D014754:Violence
D018491:Dopamine Agonists; D004873:Ergolines; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077465:Cabergoline; D000077205:Pioglitazone